Full Report

Format

Full Report
Summary (Text)
Summary (XML)

Send to:

Choose Destination

File
Clipboard
Collections

Ovarian serous cystadenocarcinoma

MedGen UID:: 83541
•Concept ID:: C0279663
•: Neoplastic Process

Synonym:	Serous ovarian cystadenocarcinoma

Monarch Initiative:	MONDO:0006046

Definition

A malignant serous cystic epithelial neoplasm arising from the ovary. It is characterized by the presence of glandular, papillary, or solid structures. Psammoma bodies may be present. In well differentiated cases the malignant epithelial cells resemble the cells of fallopian tube epithelium. In poorly differentiated cases the malignant epithelial cells show anaplastic features. [from NCI]

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVOvarian serous cystadenocarcinoma

Pathological Conditions, Signs and Symptoms
- Pathological process
  - Disease
    - Neoplasm
      - Ovarian serous cystadenocarcinoma

Professional guidelines

PubMed

APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.

Zhao S, Li Y, Xu J, Shen L
Neurol Res 2024 Mar;46(3):227-242. Epub 2024 Jan 22 doi: 10.1080/01616412.2023.2287340. PMID: 38007705

A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma.

Xiong DD, Qin Y, Xu WQ, He RQ, Wu HY, Wei DM, Zeng JJ, Dang YW, Chen G
Clin Drug Investig 2018 Oct;38(10):909-925. doi: 10.1007/s40261-018-0683-8. PMID: 30097905

Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival.

Ursic-Vrscaj M, Bebar S, Zakelj MP
Menopause 2001 Jan-Feb;8(1):70-5. doi: 10.1097/00042192-200101000-00012. PMID: 11201519

See all (4)

Recent clinical studies

Etiology

The intratumoral microbiota biomarkers for predicting survival and efficacy of immunotherapy in patients with ovarian serous cystadenocarcinoma.

Qin H, Liu J, Qu Y, Li YY, Xu YL, Yan YF
J Ovarian Res 2024 Jul 5;17(1):140. doi: 10.1186/s13048-024-01464-7. PMID: 38970121 Free PMC Article

Comprehensive analysis of the potential biological significance of cuproptosis-related gene LIPT2 in pan-cancer prognosis and immunotherapy.

Wang W, Li S, Huang Y, Guo J, Sun L, Sun G
Sci Rep 2023 Dec 21;13(1):22910. doi: 10.1038/s41598-023-50039-x. PMID: 38129565 Free PMC Article

Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.

Guo B, Wang Y, Liu W, Zhang S
Clin Transl Oncol 2023 Feb;25(2):535-554. Epub 2022 Oct 18 doi: 10.1007/s12094-022-02968-8. PMID: 36255654

Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma.

Yan JQ, Liu M, Ma YL, Le KD, Dong B, Li GH
Exp Biol Med (Maywood) 2022 Jun;247(11):910-920. Epub 2022 Mar 12 doi: 10.1177/15353702221083254. PMID: 35285286 Free PMC Article

Ancestry-specific predisposing germline variants in cancer.

Oak N, Cherniack AD, Mashl RJ; TCGA Analysis Network, Hirsch FR, Ding L, Beroukhim R, Gümüş ZH, Plon SE, Huang KL
Genome Med 2020 May 29;12(1):51. doi: 10.1186/s13073-020-00744-3. PMID: 32471518 Free PMC Article

See all (45)

Diagnosis

The intratumoral microbiota biomarkers for predicting survival and efficacy of immunotherapy in patients with ovarian serous cystadenocarcinoma.

Qin H, Liu J, Qu Y, Li YY, Xu YL, Yan YF
J Ovarian Res 2024 Jul 5;17(1):140. doi: 10.1186/s13048-024-01464-7. PMID: 38970121 Free PMC Article

APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.

Zhao S, Li Y, Xu J, Shen L
Neurol Res 2024 Mar;46(3):227-242. Epub 2024 Jan 22 doi: 10.1080/01616412.2023.2287340. PMID: 38007705

Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.

Guo B, Wang Y, Liu W, Zhang S
Clin Transl Oncol 2023 Feb;25(2):535-554. Epub 2022 Oct 18 doi: 10.1007/s12094-022-02968-8. PMID: 36255654

The circular RNA expression profile in ovarian serous cystadenocarcinoma reveals a complex circRNA-miRNA regulatory network.

Zhuang M, Zhao J, Wu J, Fu S, Han P, Song X
BMC Med Genomics 2021 Dec 2;14(Suppl 2):276. doi: 10.1186/s12920-021-01132-5. PMID: 34857007 Free PMC Article

Increased Expression of LYNX1 in Ovarian Serous Cystadenocarcinoma Predicts Poor Prognosis.

Liu H, Wang A, Ma Y
Biomed Res Int 2020;2020:1392674. Epub 2020 Nov 25 doi: 10.1155/2020/1392674. PMID: 33299855 Free PMC Article

See all (45)

Therapy

High Expression of TBC1 Domain Family Member 22A is Related to Poor Prognosis in Ovarian Serous Cystadenocarcinoma.

Lv X, Gong R, Guo L, Wang C
Int J Med Sci 2024;21(13):2603-2612. Epub 2024 Oct 7 doi: 10.7150/ijms.99744. PMID: 39439452 Free PMC Article

Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma.

Yan JQ, Liu M, Ma YL, Le KD, Dong B, Li GH
Exp Biol Med (Maywood) 2022 Jun;247(11):910-920. Epub 2022 Mar 12 doi: 10.1177/15353702221083254. PMID: 35285286 Free PMC Article

A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma.

Xiong DD, Qin Y, Xu WQ, He RQ, Wu HY, Wei DM, Zeng JJ, Dang YW, Chen G
Clin Drug Investig 2018 Oct;38(10):909-925. doi: 10.1007/s40261-018-0683-8. PMID: 30097905

Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival.

Ursic-Vrscaj M, Bebar S, Zakelj MP
Menopause 2001 Jan-Feb;8(1):70-5. doi: 10.1097/00042192-200101000-00012. PMID: 11201519

Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report.

Ohara N, Teramoto K
Clin Exp Obstet Gynecol 2000;27(2):123-4. PMID: 10968352

See all (23)

Prognosis

The intratumoral microbiota biomarkers for predicting survival and efficacy of immunotherapy in patients with ovarian serous cystadenocarcinoma.

Qin H, Liu J, Qu Y, Li YY, Xu YL, Yan YF
J Ovarian Res 2024 Jul 5;17(1):140. doi: 10.1186/s13048-024-01464-7. PMID: 38970121 Free PMC Article

ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1.

Li YK, Gao AB, Zeng T, Liu D, Zhang QF, Ran XM, Tang ZZ, Li Y, Liu J, Zhang T, Shi GQ, Zhou WC, Zou WD, Peng J, Zhang J, Li H, Zou J
J Transl Med 2024 Jan 11;22(1):46. doi: 10.1186/s12967-023-04819-8. PMID: 38212795 Free PMC Article

APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.

Zhao S, Li Y, Xu J, Shen L
Neurol Res 2024 Mar;46(3):227-242. Epub 2024 Jan 22 doi: 10.1080/01616412.2023.2287340. PMID: 38007705

Comprehensive analysis of the potential biological significance of cuproptosis-related gene LIPT2 in pan-cancer prognosis and immunotherapy.

Wang W, Li S, Huang Y, Guo J, Sun L, Sun G
Sci Rep 2023 Dec 21;13(1):22910. doi: 10.1038/s41598-023-50039-x. PMID: 38129565 Free PMC Article

Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer.

Wang Y, Zhang Y, Wang F, Li T, Song X, Shi H, Du J, Zhang H, Jing H, Han J, Tong D, Zhang J
Sci Rep 2022 Nov 2;12(1):18518. doi: 10.1038/s41598-022-21328-8. PMID: 36323715 Free PMC Article

See all (74)